血清生物标志物预测严重儿童支气管喘中的气道重塑
Alternative therapies in health and medicine
|January 31, 2024
概括
托尔类受体4 (TLR4) 和可溶性细胞间粘附分子-1 (sICAM-1) 的血清水平与严重喘儿童的呼吸道重塑有关. 这些生物标志物可以预测儿科患者喘复发的风险.
科学领域:
- 儿科肺病学 儿科肺病学
- 免疫学 免疫学 免疫学
- 生物标志物发现发现
背景情况:
- 儿童严重的支气管喘 (BA) 与呼吸道重塑有关,这一过程可能导致疾病复发.
- 确定可靠的气道改造和复发风险的生物标志物对于有效管理儿科严重的BA至关重要.
研究的目的:
- 研究血清托尔样受体4 (TLR4) 和可溶性细胞间粘附分子-1 (sICAM-1) 水平与严重BA儿童的气道改造之间的关系.
- 评估血清TLR4和sICAM-1对儿童严重BA复发的预测值.
主要方法:
- 一项回顾性研究分析了120名患有严重BA的儿童的数据,在入院时测量了血清TLR4和sICAM-1水平.
- 相关性分析 (Pearson) 检查了生物标志物和气道重塑参数 (T/D,WA%) 之间的关系.
- 二元逻辑回归和接收器操作特征 (ROC) 曲线分析评估了复发的预测值.
主要成果:
- 在1年的随访期间,复发率为38.33%. 复发的病例显示出更高的乙酸细胞计数,TLR4,sICAM-1,T/D和WA%水平.
- 血清TLR4和sICAM-1水平与气道重塑标志物 (T/D,WA%) 有积极的相关性.
- ROC分析表明,TLR4和sICAM-1,特别是在组合中,对于复发具有显著的预测值 (AUC>0.70).
结论:
- 血清TLR4和sICAM-1水平升高与严重的BA儿童的呼吸道重塑密切相关.
- 这些生物标志物显示出预测儿科患者喘复发风险的巨大潜力.
- 血清TLR4和sICAM-1的联合检测为预测严重的BA复发提供了增强的临床实用性.
相关概念视频
01:26Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:20Asthma: Pathogenesis and Management
403
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
403
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
267
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
267
01:24Asthma-III: Symptoms and Complications
2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.5K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
298
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
298